Glenmark Life Sciences Rebrands As Alivus Life Sciences Ltd.

Glenmark Life Sciences has officially changed its name to Alivus Life Sciences Ltd, starting January 20, 2025. As part of the deal, Nirma has bought 91.9 million shares, making it the new majority owner of the company. This purchase means Nirma now holds 75% of Glenmark Life Sciences’ shares from Glenmark Pharmaceuticals.

Welcoming Nirma as the company's new promoter, Mr Yasir Rawjee, managing director and chief executive officer, GLS, said, “Nirma's commitment and purpose will further strengthen our position and accelerate our growth trajectory".

As the managing director of Nirma, Hiren Karsanbhai Patel revealed that this acquisition will further complement this company’s strategies to expand in the pharmaceutical and life sciences divisions. The process of renaming is associated with the company’s new goals, which are to promote it as well as to occupy a strong position in the chosen segment of the global healthcare market.

GLS is a company that specializes in the creation and manufacture of high-added value, innovative, fine chemical products and active pharmaceutical ingredients. Currently, the company has 146 product portfolios in chronic health areas such as cardiovascular system, neurological system, pain therapeutic system and endocrine system.